179 related articles for article (PubMed ID: 34509302)
1. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Jamerson T; Rebecca VW; Aguh C
J Natl Med Assoc; 2022 Feb; 114(1):7-11. PubMed ID: 34509302
[TBL] [Abstract][Full Text] [Related]
2. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Management of Acral Lentiginous Melanoma.
Nakamura Y; Fujisawa Y
Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study.
Hong JW; Lee S; Kim DC; Kim KH; Song KH
Ann Dermatol; 2014 Apr; 26(2):195-202. PubMed ID: 24882974
[TBL] [Abstract][Full Text] [Related]
6.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
7. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
10. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America.
Castaneda CA; Torres-Cabala C; Castillo M; Villegas V; Casavilca S; Cano L; Sanchez J; Dunstan J; Calderon G; De La Cruz M; Cotrina JM; Gomez HL; Galvez R; Abugattas J
Clin Transl Oncol; 2017 Dec; 19(12):1478-1488. PubMed ID: 28577153
[TBL] [Abstract][Full Text] [Related]
11.
Ren M; Zhang J; Kong Y; Bai Q; Qi P; Zhang L; Wang Q; Zhou X; Chen Y; Zhu X
Ann Transl Med; 2022 Jan; 10(2):31. PubMed ID: 35282092
[TBL] [Abstract][Full Text] [Related]
12. TERT amplification but not activation of canonical Wnt/β-catenin pathway is involved in acral lentiginous melanoma progression to metastasis.
Ramani NS; Aung PP; Gu J; Sfamenos S; Sdringola-Maranga C; Nagarajan P; Tetzlaff MT; Curry JL; Ivan D; Diab A; Prieto VG; Hwu WJ; Torres-Cabala CA
Mod Pathol; 2020 Oct; 33(10):2067-2074. PubMed ID: 32404956
[TBL] [Abstract][Full Text] [Related]
13. Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.
Häfliger EM; Ramelyte E; Mangana J; Kunz M; Kazakov DV; Dummer R; Cheng PF
Melanoma Res; 2018 Oct; 28(5):442-450. PubMed ID: 29847461
[TBL] [Abstract][Full Text] [Related]
14. Acral melanoma: correlating the clinical presentation to the mutational status.
Ravaioli GM; Dika E; Lambertini M; Chessa MA; Fanti PA; Patrizi A
G Ital Dermatol Venereol; 2019 Oct; 154(5):567-572. PubMed ID: 29512974
[TBL] [Abstract][Full Text] [Related]
15. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
17. Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K.
Fernandes M; Barcelos D; Comodo AN; Guimarães DP; Lopes Carapeto FC; Cardili L; de Sousa Morães L; Cerutti Ap J; Landman Ap G
Am J Dermatopathol; 2019 Oct; 41(10):733-740. PubMed ID: 31021835
[TBL] [Abstract][Full Text] [Related]
18. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with
Suh MS; Choi YD; Lee JB; Lee SC; Won YH; Yun SJ
Ann Dermatol; 2018 Oct; 30(5):556-561. PubMed ID: 33911478
[TBL] [Abstract][Full Text] [Related]
20. Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan.
Wada M; Ito T; Tsuji G; Nakahara T; Hagihara A; Furue M; Uchi H
J Dermatol; 2017 Aug; 44(8):932-938. PubMed ID: 28342269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
